Nutritional and Inflammatory Measures Predict Survival of Patients with Stage IV Colorectal Cancer [post]

Yasuyuki Takamizawa, Dai Shida, Narikazu Boku, Yuya Nakamura, Yuka Ahiko, Takefumi Yoshida, Taro Tanabe, Atsuo Takashima, Yukihide Kanemitsu
2020 unpublished
Background: The present study aimed to evaluate the prognostic impact of nutritional and inflammatory measures (controlling nutritional status (CONUT) score, prognostic nutritional index (PNI) and modified Glasgow prognostic score (mGPS)) on overall survival (OS) in patients with stage IV colorectal cancer (CRC).Methods: Subjects were 996 patients with stage IV CRC who were referred to the National Cancer Center Hospital between 2001 and 2015. We retrospectively investigated correlations
more » ... OS and CONUT score, PNI, and mGPS. Multivariate analyses were performed using Cox proportional hazards regression models.Results: After adjusting for known factors (age, gender, ECOG performance status, location of primary tumor, CEA levels, histological type, M category, and prior surgical treatment), all three measures were found to be independent prognostic factors for OS in patients with stage IV CRC (CONUT score, p<0.001; PNI, p<0.001; mGPS, p<0.001). Significant differences in OS were found between low CONUT score (0/1) (n=614; 61%) and intermediate CONUT score (2/3) (n=276; 28%) (hazard ratio (HR)=1.20, p=0.031), and intermediate CONUT score and high CONUT score (≥4) (n=106; 11%) (HR=1.30, p=0.044). For mGPS, significant differences in OS were found between mGPS=0 (n=633; 64%) and mGPS=1 (n=234; 23%) (HR=1.83, p<0.001), but not between mGPS=1 and mGPS=2 (n=129; 13%) (HR=1.13, p=0.319). Patients with low PNI (<48.0) (n=443; 44%) showed a significantly lower OS rate than those with high PNI (≥48.0) (n=553; 56%) (HR=1.33, p<0.001).Conclusions: CONUT score, PNI, and mGPS were found to be independent prognostic factors for OS in patients with stage IV CRC, suggesting that nutritional and inflammatory status is a useful host-related prognostic indicator in stage IV CRC.Trial registration: retrospectively registered
doi:10.21203/rs.3.rs-39821/v1 fatcat:d7y3wh367fdarbduogqkkpv7pu